Research Article

Association between Body Mass Index and Short-Term Clinical Outcomes in Critically Ill Patients with Sepsis: A Real-World Study

Shan Lin, Shanhui Ge, Wanmei He, and Mian Zeng

Department of Medical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou, Guangdong 510080, China

Correspondence should be addressed to Mian Zeng; zengmian@mail.sysu.edu.cn

Received 3 August 2020; Revised 2 September 2020; Accepted 24 September 2020; Published 15 October 2020

Academic Editor: Flavia Prodam

Copyright © 2020 Shan Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Obesity is now recognized as one of the major public health threats, especially for patients with a critical illness. However, studies regarding whether and how body mass index (BMI) affects clinical outcomes in patients with sepsis are still scarce and controversial. The aim of our study was to determine the effect of BMI on critically ill patients with sepsis.

Materials and Methods. We performed this study using data from the Medical Information Center for Intensive Care III database. A multivariate Cox regression model was used to assess the independent association of BMI with the primary outcome.

Results. A total of 7,967 patients were enrolled in this study. Firstly, we found that the 28-day mortality was reduced by 22% (HR = 0.78, 95% CI 0.69–0.88) and 13% (HR = 0.87, 95% CI 0.78–0.98) for obese and overweight compared to normal weight, respectively. Subsequently, a U-shaped association of BMI with 28-day mortality was observed in sepsis patients, with the lowest 28-day mortality at the BMI range of 30–40 kg/m². Finally, significant interactions were observed only for sex (P = 0.0071). Male patients with a BMI of 25–30 kg/m² (HR = 0.74, 95% CI 0.63–0.86) and 30–40 kg/m² (HR = 0.63, 95% CI 0.53–0.76) had a significantly lower risk of 28-day mortality.

Conclusions. A U-shaped association of BMI with 28-day mortality in critically ill sepsis patients was found, with the lowest 28-day mortality at a BMI range of 30–40 kg/m². Notably, male patients were protected by a higher BMI more effectively than female patients as males had a significantly lower mortality risk.

1. Introduction

With the rapidly increasing prevalence of obesity, healthcare professionals are faced with an increasing number of obese patients with a critical illness [1, 2]. Obesity is currently one of the major public health threats, which affects almost all physiological functions. Multiple investigators hold that this phenomenon of increased BMI or obesity will develop a detrimental effect in morbidity and mortality from obesity-related diseases, such as diabetes mellitus, cardiovascular disease, poor mental health, musculoskeletal diseases, and several types of cancer [3–6]. However, there are controversies over the evidence available for the mortality caused by overweight and obesity. Various studies have shown a U-shaped association between BMI and population mortality, with the highest risk of death in underweight and overweight populations [7–11].

Sepsis is an acute life-threatening organ dysfunction secondary to infection, and morbidity and mortality rates remain high [12–14]. Currently, it has yet to be established whether the mortality rate among sepsis patients is truly related to their BMI and, if so, to what extent. Accordingly, it is well worth exploring the correlation between BMI and the short-term prognosis of patients with sepsis. Given this, we aimed to assess the impact of BMI on critically ill patients with sepsis upon admission to the intensive care unit (ICU).

2. Materials and Methods

2.1. Patient Data. We conducted this study in the Medical Information Center for Intensive Care (MIMIC-III) database [15]. The Institutional Review Boards of the Beth Israel Deaconess Medical Center and MIT-affiliated institutions have approved access to this database (record ID: 33460949).
Patient consent was waived due to the retrospective study and the anonymity of the data.

All patients’ data (age ≥ 18 years) with a diagnosis of sepsis-3 based on a sequential organ failure assessment (SOFA) score of ≥2 and suspected infection within the first day of ICU admission during the period 2002 to 2012 were included [12, 16]. BMI was calculated by weight and height measured on the first day of ICU admission. Patients with missing weight or height parameters and a BMI of less than 10 kg/m² or more than 60 kg/m² were excluded. In compliance with the World Health Organization BMI classification, patients were categorized as follows: the underweight group (BMI < 18.5 kg/m²), the normal group (BMI ≥ 18.5, <25 kg/m²), the overweight group (BMI ≥ 25, <30 kg/m²), and the obese group (BMI ≥ 30 kg/m²). As mentioned in our previous study, structured query language (SQL) was used to extract data in the software Navicat Premium [17]. The code and website used for the MIMIC-III database are publicly available [18].

2.2. Outcomes. The primary clinical outcome was 28-day mortality, and the secondary outcome was ICU mortality.

2.3. Statistical Analysis. Data were expressed as median (Q1–Q3) or mean ± standard deviation (SD) for continuous variables and as numbers and percentages for categorical variables. We used the Chi-square test (for categorical variables) and one-way analysis of variance (for continuous variables) to compare differences in patient characteristics between groups. To begin, we utilized Cox regression and logistic regression models to investigate the independent roles of BMI categories in relation to the primary and secondary outcomes. Initially, the Cox regression model was adjusted for demographic factors, treatment, and disease severity scores. Next, we replaced the Elixhauser Comorbidity Index (SID30) [19] score with specific diseases to more accurately assess the independent effect of BMI on outcomes.

Subsequently, to determine if there was a U-shaped association between 28-day mortality rate and BMI, nonlinear regression analyses using the Cox model were conducted to fit the clinical outcome. A two-piecewise linear regression model and a log-likelihood ratio test were used to screen for the presence of a threshold effect of 28-day mortality. The inflection points were shown using threshold effect analysis. The confidence interval of the inflection point was calculated through the bootstrap method [20]. Age- and sex-adjusted Kaplan-Meier’s (K-M) curves were used to assess the effect of the new BMI category on 28-day mortality. Lastly, we also performed interaction tests and stratified analyses on variables such as age (<65 and ≥65 years), sex, and SOFA score (<5, 5-10, 10-15, and ≥15). All data were collected using EmpowerStats (R) (http://www.empowerstats.com), X & Y Solutions, Inc., Boston, Massachusetts, USA) and R (http://www.R-project.org, version 3.4.3) for analysis. A P value of less than 0.05 was considered significant.

3. Results

3.1. Characteristics of the Study Population. Data of 7,967 patients were used in this study (Table 1 and Figure 1). The mean age of the study population was 65.92 ± 15.98 years, and the mean age of overweight and obese patients was markedly lower than that of normal and underweight patients (P < 0.001). Males accounted for 55.25% of all participants. The median SOFA scores were higher in overweight and obese patients than in normal and underweight patients (P < 0.001), while the median SID30 scores, however, were lower than those of normal and underweight patients. A higher proportion of obese patients required mechanical ventilation on the first day of ICU admission than in the remaining three groups. No statistically significant differences were observed in renal replacement therapy between BMI categories on the first day, whereas statistically significant differences were not observed among the groups requiring renal replacement therapy on the first day. Comparisons with the underweight, overweight, and obese groups using normal weight as a reference are placed in Tables S1–S3.

3.2. Clinical Outcomes of Participants. Overall, hospital mortality and ICU mortality were dramatically lower in the obese group than in the normal weight group (19.14% vs. 24.00%, P < 0.001 and 13.81% vs. 17.35%, P = 0.005) (Table 1). On day 28, 1,667 patients (20.92%) died after ICU admission. In addition, obese patients had a lower 28-day mortality rate in comparison to normal weight patients (17.49% vs. 23.76%, P < 0.001). However, compared with overweight, normal, and underweight patients, obese patients suffered longer lengths of ICU and hospital stay (P < 0.001).

3.3. Associations between BMI and Clinical Outcomes. The multivariate Cox regression analysis showed that overweight and obese patients were protected against 28-day mortality, with crude risk ratios of 0.87 (95% CI 0.77–0.98) and 0.71 (95% CI 0.63–0.80), respectively. After adjustment, we found that overweight and obese were still not risk factors, and the results were consistent and significant across the adjusted models (Table 2). In model II, the 28-day mortality was reduced by 22% (HR 0.78, 95% CI 0.69–0.88, P = 0.0001) and 13% (HR 0.87, 95% CI 0.78–0.98, P = 0.0263) for the obese and overweight groups compared to the normal weight group, respectively. Similar results were also found for ICU mortality (Table 2). In model II, the multivariate logistic regression analysis revealed that there was a relatively low risk of ICU mortality in the obese group (OR 0.77, 95% CI 0.65–0.91, P = 0.0023).

Smooth curve fitting showed a U shape as the 28-day mortality rate decreased with increasing BMI before the inflection point (Figure 2). By using the threshold effect analysis, the inflection point was determined as 38.68 kg/m² (95% CI 26.49–40.99 kg/m²) for the 28-day mortality rate. The threshold effect of BMI on the 28-day mortality group was significant after adjusting for potential confounders. The hazard ratio was 0.97 for BMI < 38.68 kg/m² and 1.05 for BMI ≥ 38.68 kg/m² for the 28-day mortality rate (Table 3). The log-likelihood ratio test was less than 0.001.

Based on the 95% confidence interval of the inflection point calculated by the bootstrap method, we divided the BMI between 30 and 40 kg/m² into a separate group; the 28-day mortality across fitted groups of new BMI categories
| Parameters                          | All patients | Underweight (<18.5 kg/m²) | Normal (≥18.5, <25 kg/m²) | Overweight (≥25, <30 kg/m²) | Obese (≥30 kg/m²) | P value |
|------------------------------------|--------------|----------------------------|----------------------------|------------------------------|-------------------|---------|
| N                                  | 7967         | 325                        | 2513                       | 2465                         | 2664              | <0.001  |
| Age (years)                        | 65.92 ± 15.98| 67.02 ± 17.6              | 67.56 ± 16.88              | 66.51 ± 16.21                | 63.71 ± 14.36     |         |
| Sex, n(%)                          |              |                            |                            |                              |                   | <0.001  |
| Male                               | 4402 (55.25%)| 155 (47.69%)               | 1363 (54.24%)              | 1486 (60.28%)                | 1398 (52.48%)     |         |
| Female                             | 3565 (44.75%)| 170 (52.31%)               | 1150 (45.76%)              | 979 (39.72%)                 | 1266 (47.52%)     |         |
| SOFA                               | 5.00 (3.00-8.00) | 4.00 (3.00-8.00) | 5.00 (3.00-8.00) | 6.00 (4.00-8.00) | 6.00 (4.00-8.00) | <0.001  |
| Elixhauser Comorbidity Index (SID30) | 19.00 (10.00-29.00) | 21.00 (12.00-31.00) | 20.00 (11.00-30.00) | 20.00 (11.00-29.00) | 18.00 (9.00-28.00) | <0.001  |
| Mechanical ventilation on the first day | 4918 (61.73%) | 175 (53.85%)               | 1493 (59.41%)              | 1511 (61.30%)                | 1739 (65.28%)     |         |
| Renal replacement therapy on the first day | 536 (6.73%) | 18 (5.54%)                  | 152 (6.05%)                | 169 (6.86%)                  | 197 (7.39%)       | 0.209   |
| Length of hospital stay (days)     | 14.46 (8.15-24.69) | 11.86 (7.07-21.86) | 13.66 (7.73-23.58) | 14.64 (8.32-24.99) | 15.51 (8.91-25.39) | <0.001  |
| Length of ICU stay (days)          | 5.85 (2.80-12.04) | 4.38 (2.22-8.99)           | 5.23 (2.53-11.16)          | 5.86 (2.86-11.92)            | 6.50 (3.05-13.30) | <0.001  |
| Hospital mortality, n (%)          | 1723 (21.63%) | 77 (23.69%)                 | 603 (24.00%)               | 533 (21.62%)                 | 510 (19.14%)      | <0.001  |
| ICU mortality, n (%)               | 1254 (15.74%) | 53 (16.31%)                 | 436 (17.35%)               | 397 (16.11%)                 | 368 (13.81%)      | 0.005   |
| Comorbidities, n (%)               | 1667 (20.92%) | 89 (27.38%)                 | 597 (23.76%)               | 515 (20.89%)                 | 466 (17.49%)      | <0.001  |
| Congestive heart failure           | 3194 (40.09%) | 107 (32.92%)                | 972 (38.68%)               | 979 (39.72%)                 | 1136 (42.64%)     | <0.001  |
| Cardiac arrhythmias                | 3047 (38.25%) | 85 (26.15%)                 | 989 (39.36%)               | 936 (37.97%)                 | 1037 (38.93%)     | <0.001  |
| Valvular disease                   | 1317 (16.53%) | 49 (15.08%)                 | 447 (17.79%)               | 403 (16.35%)                 | 418 (15.69%)      | 0.187   |
| Peripheral vascular disease        | 1133 (14.22%) | 57 (17.54%)                 | 387 (15.40%)               | 365 (14.81%)                 | 324 (12.16%)      | 0.001   |
| Hypertension                       | 4326 (54.30%) | 129 (39.69%)                | 1286 (51.17%)              | 1332 (54.04%)                | 1579 (59.27%)     | <0.001  |
| Other neurological disease         | 1130 (14.18%) | 62 (19.08%)                 | 387 (15.40%)               | 369 (14.97%)                 | 312 (11.71%)      | <0.001  |
| Chronic pulmonary disease          | 1913 (24.01%) | 102 (31.38%)                | 602 (23.96%)               | 529 (21.46%)                 | 680 (25.53%)      | <0.001  |
| Liver disease                      | 987 (12.39%)  | 39 (12.00%)                 | 276 (10.98%)               | 310 (12.58%)                 | 362 (13.99%)      | 0.041   |
| Renal failure                      | 1806 (22.67%) | 67 (20.62%)                 | 523 (20.81%)               | 588 (23.85%)                 | 628 (23.57%)      | 0.030   |
| AIDS                               | 104 (1.31%)   | 7 (2.15%)                   | 56 (2.23%)                 | 28 (1.14%)                   | 13 (0.49%)        | <0.001  |
| Lymphoma                           | 216 (2.71%)   | 12 (3.69%)                  | 68 (2.71%)                 | 72 (2.92%)                   | 64 (2.40%)        | 0.464   |
| Metastatic cancer                  | 436 (5.47%)   | 24 (7.38%)                  | 172 (6.84%)                | 151 (6.13%)                  | 89 (3.34%)        | <0.001  |
| Solid tumor                        | 386 (4.84%)   | 29 (8.92%)                  | 129 (5.13%)                | 112 (4.54%)                  | 116 (4.35%)       | 0.003   |
| Diabetes                           | 2468 (30.98%) | 45 (13.85%)                 | 553 (22.01%)               | 713 (28.92%)                 | 1157 (43.43%)     | <0.001  |
| Fluid and electrolyte disorders    | 3876 (48.65%) | 163 (50.15%)                | 1221 (48.59%)              | 1201 (48.72%)                | 1291 (48.46%)     | 0.952   |
| Alcohol abuse                      | 625 (7.84%)   | 14 (4.31%)                  | 196 (7.80%)                | 200 (8.11%)                  | 215 (8.07%)       | 0.108   |
| Drug abuse                         | 291 (3.65%)   | 9 (2.77%)                   | 117 (4.66%)                | 84 (3.41%)                   | 81 (3.04%)        | 0.011   |
| Depression                         | 791 (9.93%)   | 35 (10.77%)                 | 211 (8.40%)                | 245 (9.94%)                  | 300 (11.26%)      | 0.007   |

Data are expressed as median (Q1–Q3) or mean ± standard deviation (SD) for continuous variables and as numbers and percentages for categorical variables. Chi-square tests (for categorical variables) and one-way analysis of variance (for continuous variables) were used to compare differences in patient characteristics between groups. Abbreviations: ICU—intensive care unit; SOFA—sequential organ failure assessment; AIDS—acquired immune deficiency syndrome.
is presented in Figure 3. The K-M curves showed that there were significant survival characteristics in patients with the BMI range of 30–40 kg/m² after adjusting age and sex (log-rank test: \( P < 0.0001 \)) (Figure 4).

In the stratified analysis, the association between the new BMI categories and the risk of 28-day mortality was similar for most strata (\( P > 0.05 \)) (Table 4). A significant interaction was observed only for sex (\( P = 0.0071 \)). Male patients were protected by a higher BMI more effectively than female patients as males had a significantly lower mortality risk. Male patients with a BMI of 25–30 kg/m² and 30–40 kg/m² had a significantly lower risk of 28-day mortality (HR 0.74, 95% CI 0.63–0.86, \( P = 0.0001 \) and HR 0.63, 95% CI 0.53–0.76, \( P < 0.0001 \), respectively). However, in the case of female patients, a 47% increased 28-day mortality was observed only in patients with a BMI < 18.5 kg/m² (HR 1.47, 95% CI 1.09–2.00).

### 4. Discussion

In this study, we selected a specific study population with sepsis-3 from MIMIC-III database (\( N = 8,154 \))

- Excluding patients younger than 18 years old (\( N = 5 \))
- Excluding patients with missing weight or height parameters (\( N = 109 \))
- Excluding patients with a BMI less than 10 and greater than 60 (\( N = 73 \))

**The final cohort** (\( N = 7,967 \))

**Figure 1: Flow chart for the selection of study participants.**

Excluding patients younger than 18

Excluding patients with missing

Excluding patients with a BMI less

The opinion that obesity can lead to multiple diseases due to a less healthy lifestyle is largely accepted. The condition of obese patients is almost not optimistic when seriously ill. In the general population, BMI itself can be a powerful predictor of the overall mortality rate when it is outside the range of the optimal BMI (23–25 kg/m²) [11, 21]. On the contrary, in patients who are overweight or obese, BMI and overall mortality have an inverse relationship, known as “obesity paradox” [22, 23]. A cohort study of 55,038 adult patients claimed that the short-term mortality rate was lower in patients with higher BMI after unadjusted and adjusted analyses [24]. Similarly, an observational cohort study showed a negative association between obesity and hospital mortality in critically ill patients [25]. Additionally, another meta-analysis revealed an inverse association between overweight (BMI between 25 and 29.9 kg/m²) or obesity (BMI between 30 and 39.9 kg/m²) and mortality in critically ill patients [26]. Similarly, in four other recent meta-analyses, obesity.

### Table 2: Associations between BMI categories and clinical outcomes.

|                | Groups       | HR (95% CI) | \( P \) value |
|----------------|--------------|-------------|---------------|
| **28-day mortality** |             |             |               |
| Crude          | Normal       | 1.0         | —             |
|                | Underweight  | 1.17 (0.94-1.47) | 0.1609 |
|                | Overweight   | 0.87 (0.77-0.98) | 0.0175 |
|                | Obese        | 0.71 (0.63-0.80) | <0.0001 |
| Model I        | Normal       | 1.0         | —             |
|                | Underweight  | 1.20 (0.96-1.50) | 0.1117 |
|                | Overweight   | 0.86 (0.76-0.97) | 0.0130 |
|                | Obese        | 0.75 (0.66-0.84) | <0.0001 |
| Model II       | Normal       | 1.0         | —             |
|                | Underweight  | 1.16 (0.93-1.46) | 0.1845 |
|                | Overweight   | 0.87 (0.78-0.98) | 0.0263 |
|                | Obese        | 0.78 (0.69-0.88) | 0.0001 |

**ICU mortality**

|                | Groups       | OR (95% CI) | \( P \) value |
|----------------|--------------|-------------|---------------|
| Crude          | Normal       | 1.0         | —             |
|                | Underweight  | 0.93 (0.68-1.27) | 0.6398 |
|                | Overweight   | 0.91 (0.79-1.06) | 0.2397 |
|                | Obese        | 0.76 (0.66-0.89) | 0.0005 |
| Model I        | Normal       | 1.0         | —             |
|                | Underweight  | 1.01 (0.73-1.41) | 0.9365 |
|                | Overweight   | 0.86 (0.73-1.01) | 0.0578 |
|                | Obese        | 0.73 (0.62-0.85) | 0.0001 |
| Model II       | Normal       | 1.0         | —             |
|                | Underweight  | 0.97 (0.70-1.36) | 0.8721 |
|                | Overweight   | 0.87 (0.74-1.02) | 0.0902 |
|                | Obese        | 0.77 (0.65-0.91) | 0.0023 |

Cox regression models and logistic regression models were used to examine the independent role of BMI category in relation to 28-day and ICU mortality. Model I was adjusted by age, sex, SOFA, Elixhauser Comorbidity Index (SID30), mechanical ventilation on the first day, and renal replacement therapy on the first day. Model II was adjusted by age, sex, SOFA, mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmias, valvular disease, peripheral vascular disease, hypertension, other neurological diseases, chronic pulmonary disease, liver disease, renal failure, AIDS, lymphoma, metastatic cancer, solid tumor, diabetes, fluid and electrolyte disorders, alcohol abuse, drug abuse, and depression. Abbreviations: HR—hazard ratio; OR—odds ratio; CI—confidence interval; SOFA—sequential organ failure assessment; AIDS—acquired immune deficiency syndrome.
was found to be markedly associated with reduced mortality in critically ill patients [27–30].

In contrast to our findings and the results above, a retrospective study of 1,191 adults admitted with severe sepsis showed that the adjusted 28-day mortality rate was neither significantly increased nor decreased in obese or morbidly obese patients compared to that of normal weight patients [31]. A meta-analysis including 22 studies, with a total of 88,051 patients, indicated that obesity did not impact the mortality rate of patients admitted to the ICU [32]. Additionally, another meta-analysis conducted by Akinnusi involving

**Table 3: Threshold effect analysis of BMI and 28-day mortality.**

| Inflection point | HR   | 95% CI  | P value |
|------------------|------|---------|---------|
| <38.68 kg/m²     | 0.97 | 0.96-0.98 | <0.0001 |
| ≥38.68 kg/m²     | 1.05 | 1.03-1.08 | <0.0001 |

The log-likelihood ratio test: $P < 0.001$

The confidence interval of the inflection point: 26.49–40.99 kg/m²

A two-piecewise linear regression model and a log-likelihood ratio test were used to explore for the presence of a threshold effect of 28-day mortality, and inflection points are shown using threshold effect analysis, with confidence interval of the inflection point calculated by the bootstrap method. Note: adjusted by age, sex, SOFA, mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmias, valvular disease, peripheral vascular disease, hypertension, other neurological diseases, chronic pulmonary disease, liver disease, renal failure, AIDS, lymphoma, metastatic cancer, solid tumor, diabetes, fluid and electrolyte disorders, alcohol abuse, drug abuse, and depression. Abbreviations: BMI—body mass index; HR—hazard ratio; CI—confidence interval.

**Figure 2:** Association between BMI and 28-day mortality. Notes: adjusted by age, sex, SOFA, mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmias, valvular disease, peripheral vascular disease, hypertension, other neurological diseases, chronic pulmonary disease, liver disease, renal failure, AIDS, lymphoma, metastatic cancer, solid tumor, diabetes, fluid and electrolyte disorders, alcohol abuse, drug abuse, and depression.

**Figure 3:** The 28-day mortality across fitted groups of new BMI categories. Notes: adjusted by age, sex, SOFA, mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmias, valvular disease, peripheral vascular disease, hypertension, other neurological diseases, chronic pulmonary disease, liver disease, renal failure, AIDS, lymphoma, metastatic cancer, solid tumor, diabetes, fluid and electrolyte disorders, alcohol abuse, drug abuse, and depression.

**Figure 4:** Kaplan-Meier’s survival curve by new BMI categories in 28-day mortality adjusting age and sex.
Table 4: Effect size of new BMI categories on 28-day mortality rate in prespecified and exploratory subgroups in each subgroup.

| Outcomes: 28-year mortality BMI (kg/m²) | Crude HR (95% CI) | Crude P value | Adjusted model HR (95% CI) | Adjusted model P value | P interaction |
|----------------------------------------|-------------------|---------------|--------------------------|------------------------|---------------|
| **Age (years): <65**                  |                   |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 1.0               | —             | 1.0                      | —                      | 0.6539        |
| ≥25, <30                              | 0.99 (0.71-1.43)  | 0.3959        | 1.03 (0.74-1.40)         | 0.6271                 |               |
| ≥30, <40                              | 0.65 (0.44-0.96)  | 0.0245        | 0.71 (0.52-0.97)         | 0.0303                 |               |
| ≥40                                   | 0.55 (0.34-0.90)  | 0.0230        | 0.60 (0.40-0.90)         | 0.0230                 |               |
| **Age (years): ≥65**                  |                   |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 1.0               | —             | 1.0                      | —                      | 0.0071        |
| ≥25, <30                              | 0.77 (0.66-0.89)  | 0.0077        | 0.76 (0.65-0.90)         | 0.0077                 |               |
| ≥30, <40                              | 0.53 (0.45-0.63)  | <0.0001       | 0.63 (0.54-0.73)         | <0.0001                |               |
| ≥40                                   | 0.50 (0.39-0.62)  | 0.0003        | 0.62 (0.51-0.75)         | 0.0003                 |               |
| **Sex: male**                         |                   |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.68 (0.50-0.91)  | 0.0220        | 0.90 (0.64-1.27)         | 0.5562                 |               |
| ≥25, <30                              | 0.77 (0.66-0.89)  | 0.0077        | 0.74 (0.63-0.86)         | 0.0001                 |               |
| ≥30, <40                              | 0.52 (0.44-0.60)  | <0.0001       | 0.64 (0.53-0.76)         | <0.0001                |               |
| ≥40                                   | 0.55 (0.45-0.64)  | 0.0003        | 0.65 (0.54-0.76)         | 0.0003                 |               |
| **Sex: female**                       |                   |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.74 (0.64-0.85)  | 0.0260        | 0.90 (0.64-1.27)         | 0.5562                 |               |
| ≥25, <30                              | 0.80 (0.68-0.94)  | 0.0006        | 0.90 (0.64-1.27)         | 0.5562                 |               |
| ≥30, <40                              | 0.59 (0.52-0.69)  | 0.0006        | 0.63 (0.54-0.74)         | 0.0006                 |               |
| ≥40                                   | 0.60 (0.48-0.76)  | 0.0006        | 0.63 (0.54-0.74)         | 0.0006                 |               |
| **Mechanical ventilation on first day: no** |             |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.69 (0.58-0.83)  | 0.0006        | 0.81 (0.67-0.98)         | 0.0045                 |               |
| ≥25, <30                              | 0.84 (0.73-0.97)  | 0.0006        | 0.92 (0.76-1.13)         | 0.4268                 |               |
| ≥30, <40                              | 0.75 (0.60-0.95)  | 0.0006        | 0.90 (0.64-1.27)         | 0.5562                 |               |
| ≥40                                   | 0.67 (0.56-0.80)  | 0.0006        | 0.82 (0.54-0.89)         | 0.0006                 |               |
| **Mechanical ventilation on first day: yes** |             |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.75 (0.28-2.02)  | 0.4650        | 0.74 (0.28-1.93)         | 0.5383                 |               |
| ≥25, <30                              | 0.80 (0.64-1.36)  | 0.0144        | 0.83 (0.55-1.21)         | 0.3076                 |               |
| ≥30, <40                              | 0.61 (0.40-0.94)  | 0.0258        | 0.66 (0.40-0.99)         | 0.0433                 |               |
| ≥40                                   | 0.45 (0.22-0.92)  | 0.0284        | 0.50 (0.23-1.05)         | 0.0678                 |               |
| **Renal replacement therapy on first day: no** |             |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.70 (0.61-0.80)  | 0.0001        | 0.76 (0.66-0.88)         | 0.0002                 |               |
| ≥25, <30                              | 0.73 (0.59-0.90)  | 0.0006        | 0.84 (0.65-1.08)         | 0.1728                 |               |
| ≥30, <40                              | 0.73 (0.59-0.90)  | 0.0006        | 0.84 (0.65-1.08)         | 0.1728                 |               |
| **Renal replacement therapy on first day: yes** |             |               |                          |                        |               |
| ≥18.5, <25                            |                   |               |                          |                        |               |
| <18.5                                 | 0.71 (0.58-0.88)  | 0.0260        | 0.74 (0.64-0.99)         | 0.0433                 |               |
| ≥25, <30                              | 0.80 (0.64-0.94)  | 0.0144        | 0.88 (0.68-1.12)         | 0.3076                 |               |
| ≥30, <40                              | 0.61 (0.40-0.94)  | 0.0258        | 0.66 (0.40-0.99)         | 0.0433                 |               |
| ≥40                                   | 0.45 (0.22-0.92)  | 0.0284        | 0.50 (0.24-1.05)         | 0.0678                 |               |
62,045 critically ill patients found that obesity was not correlated with an elevated risk of death in the ICUs. Nevertheless, the survival rate of obese patients with a BMI between 30 and 39.9 kg/m² was improved, which was in accordance with the results of Oliveros et al. [33]. However, the meta-analysis of observational studies should be construed cautiously, and the evidence of association should not be mistaken for proof of causality. Importantly, these meta-analyses did not make any adjusting for disease severity or age. Furthermore, the BMIs were inaccurate since fluid overload led to pseudoobesity in certain cases, which ultimately affected the outcomes. Such inconsistencies were also observed in the retrospective studies. Finally, some studies reported losing a large amount of data, and heterogeneity could be found in data collection from included studies.

Hence, it is still unclear whether the obesity paradox exists as the underlying physiological mechanisms are not fully understood. Some evidence-based explanations are as follows: (a) A higher BMI means that a higher nutritional reserve is available, which is essential for surviving an acute life-threatening illness. (b) Adipose tissue regulates the inflammatory response by secreting anti-inflammatory mediators such as leptin, interleukin-10 (IL-10), and soluble tumor necrosis factor receptor 2 [34–36]. Earlier studies suggested that in critically ill patients with sepsis, lower levels of plasma IL-10 were associated with poor prognosis [37]. Similarly, serum leptin levels were significantly higher in sepsis survivors [38]. (c) High-density lipoproteins in obese patients can bind to bacterial endotoxins, which in turn is beneficial during sepsis [36]. (d) increased renin-angiotensin system activation may confer hemodynamic advantages in sepsis [39]. Nevertheless, these potential mechanisms are based on the guesswork of basic research. The beneficial effects of obesity cannot be explained yet as the determination of body fat distribution through BMI calculation is not possible.

There were also several limitations in our study. We tried to exclude the effects of “false obesity” due to interventions by extracting the first BMI after ICU admission. However, we still cannot determine whether the interventions that patients have received before ICU admission may affect BMI, such as intra-venous infusions. Compared with the inclusion criteria by ICD-9 code in the previous study [40], we used the sepsis-3 diagnostic criteria to enroll the study population. Moreover,

| BMI (kg/m²) | Crude HR (95% CI) | P value | Adjusted model HR (95% CI) | P value | P interaction |
|------------|------------------|---------|---------------------------|---------|---------------|
| ≥18.5, <25 | 1.0              | —       | 1.0                       | —       | 0.7859        |
| <18.5      | 1.22 (0.85-1.75) | 0.2771  | 1.14 (0.79-1.64)          | 0.4928  |               |
| ≥25, <30   | 0.81 (0.65-1.02) | 0.0693  | 0.87 (0.70-1.09)          | 0.2383  |               |
| ≥30, <40   | 0.54 (0.42-0.71) | <0.0001 | 0.68 (0.52-0.90)          | 0.0066  |               |
| ≥40        | 0.53 (0.34-0.83) | 0.0055  | 0.85 (0.53-1.36)          | 0.5003  |               |
| ≥5, <10    | 1.0              | —       | 1.0                       | —       |               |
| ≥18.5, <25 | 1.29 (0.92-1.82) | 0.1359  | 1.18 (0.84-1.66)          | 0.3522  |               |
| ≥25, <30   | 0.79 (0.66-0.95) | 0.0101  | 0.81 (0.67-0.97)          | 0.0204  |               |
| ≥30, <40   | 0.68 (0.56-0.82) | <0.0001 | 0.75 (0.61-0.92)          | 0.0049  |               |
| ≥40        | 0.65 (0.48-0.87) | 0.0043  | 0.91 (0.67-1.25)          | 0.5768  |               |
| ≥10, <15   | 1.0              | —       | 1.0                       | —       |               |
| ≥18.5, <25 | 1.19 (0.70-2.04) | 0.5200  | 1.19 (0.69-2.05)          | 0.5380  |               |
| ≥25, <30   | 0.89 (0.69-1.14) | 0.3466  | 0.93 (0.72-1.20)          | 0.5749  |               |
| ≥30, <40   | 0.76 (0.58-1.00) | 0.0484  | 0.80 (0.61-1.06)          | 0.1191  |               |
| ≥40        | 0.77 (0.53-1.13) | 0.1849  | 0.95 (0.64-1.41)          | 0.7995  |               |
| ≥15        | 1.0              | —       | 1.0                       | —       |               |
| ≥18.5, <25 | 0.91 (0.12-6.73) | 0.9286  | 1.45 (0.16-13.38)         | 0.7433  |               |
| ≥25, <30   | 1.17 (0.69-1.96) | 0.5608  | 1.24 (0.67-2.30)          | 0.4842  |               |
| ≥30, <40   | 0.71 (0.40-1.27) | 0.2480  | 0.67 (0.36-1.26)          | 0.2124  |               |
| ≥40        | 0.93 (0.42-2.05) | 0.8544  | 0.83 (0.33-2.06)          | 0.6863  |               |

Interaction tests and stratified analyses explored the relationship between the new BMI categories across subgroup variables. Note: adjusted for age, sex, SOFA, mechanical ventilation on the first day, renal replacement therapy on the first day, congestive heart failure, cardiac arrhythmia, valvular disease, peripheral vascular disease, hypertension, other neurological diseases, chronic pulmonary disease, liver disease, renal failure, AIDS, lymphoma, metastatic cancer, solid tumor, diabetes, fluid and electrolyte disorders, alcohol abuse, drug abuse, and depression except for the subgroup variable. Abbreviations: BMI—body mass index; HR—hazard ratio; CI—confidence interval.
our study took into account the effect of comorbidities, and, to our knowledge, this is the first time a U-shaped relationship between BMI and 28-day mortality has been found. These findings were one strength of our research that was different from previous studies. But it cannot be ignored that we assumed a baseline SOFA score of 0 points prior to ICU admission and thus used a SOFA ≥ 2 points to include patients, which may result in overinclusion of patients; similarly, we did not consider biomarkers like PCT and interleukins, which would potentially have an impact on outcomes. Other limitations included selection bias in a retrospective study, a single-center design, and low external validity. Therefore, well-designed prospective multicenter studies are definitely required to further confirm our findings.

5. Conclusion

In this study, we found a U-shaped relationship between BMI and 28-day mortality in critically ill sepsis patients, with the lowest 28-day mortality at a BMI range of 30–40 kg/m². Notably, male patients were protected by a higher BMI more effectively than female patients as males had a significantly lower mortality risk.

Abbreviations

BMI: Body mass index
ICU: Intensive care unit
SOFA: Sequential organ failure assessment
MIMIC-III: Medical Information Center for Intensive Care III
SQL: Structure query language
OR: Odds ratio
HR: Hazard ratio
CI: Confidence interval
AIDS: Acquired immune deficiency syndrome
K-M: Kaplan-Meier
SID30: Elixhauser Comorbidity Index.

Data Availability

The raw data itself is from a third-party dataset available from MIMIC-III, a freely accessible critical care database. https://mimic.physionet.org/gettingstarted/access.

Conflicts of Interest

All authors claim no conflicts of interest. All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

Authors’ Contributions

Shan Lin designed the study and wrote the draft of this manuscript. Shan Lin and Shanhui Ge mainly performed data extraction and statistical analysis. Wanmei He prepared the tables and figures. Mian Zeng revised this manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant number: 81670066); the Science and Technology Planning Project of Guangdong Province, China (Grant number: 2016A020216009); the Critical Care Research Funding of the Aesclap Academy (2017); and the Guangdong Basic and Applied Basic Research Foundation, China (Grant number: 2019A1515011198).

Supplementary Materials

Table S1: Characteristics of normal and underweight groups.
Table S2: Characteristics of normal and overweight groups.
Table S3: Characteristics of normal and obese groups. (Supplementary Materials)

References

[1] Global Burden of Disease Study 2015, Global Burden of Disease Study 2015 (GBD 2015). Obesity and Overweight Prevalence 1980-2015, Institute for Health Metrics and Evaluation (IHME), Seattle, United States, 2017.
[2] Y. C. Chooi, C. Ding, and F. Magkos, "The epidemiology of obesity," Metabolism, vol. 92, pp. 6–10, 2019.
[3] E. W. Gregg and J. E. Shaw, "Global health effects of overweight and obesity," The New England Journal of Medicine, vol. 377, no. 1, pp. 80-81, 2017.
[4] B. Lauhy-Secretan, C. Scoccianti, D. Loomis et al., "Body fatness and cancer—viewpoint of the IARC Working Group," The New England Journal of Medicine, vol. 375, no. 8, pp. 794–798, 2016.
[5] A. Anandacoomarasamy, M. Fransen, and L. March, "Obesity and comorbid mental health, developmental, and physical health conditions in a nationally representative sample of US children aged 10 to 17," Academic Pediatrics, vol. 13, no. 1, pp. 6–13, 2013.
[6] N. Halfon, K. Larson, and W. Slusser, "Associations between obesity and comorbid mental health, developmental, and physical health conditions in a nationally representative sample of US children aged 10 to 17," Academic Pediatrics, vol. 13, no. 1, pp. 6–13, 2013.
[7] K. F. Adams, A. Schatzkin, T. B. Harris et al., "Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old," The New England Journal of Medicine, vol. 355, no. 8, pp. 763–778, 2006.
[8] K. M. Flegal, B. I. Graubard, D. F. Williamson, and M. H. Gail, "Excess deaths associated with underweight, overweight, and obesity," Journal of the American Medical Association, vol. 293, no. 15, pp. 1861–1867, 2005.
[9] Prospective Studies Collaboration, "Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies," The Lancet, vol. 373, no. 9669, pp. 1083–1096, 2009.
[10] D. L. McGee, "Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies," Annals of Epidemiology, vol. 15, no. 2, pp. 87–97, 2005.
[11] T. Pischon, H. Boeing, K. Hoffmann et al., "General and abdominal adiposity and risk of death in Europe," The New England Journal of Medicine, vol. 359, no. 20, pp. 2105–2120, 2008.
[12] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),” *Journal of the American Medical Association*, vol. 315, no. 8, pp. 801–810, 2016.

[13] C. Fleischmann, A. Scherag, N. K. N. Adhikari et al., “Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and limitations,” *American Journal of Respiratory and Critical Care Medicine*, vol. 193, no. 3, pp. 259–272, 2016.

[14] C. Rhee, R. Rantes, L. Epstein et al., “MIMIC-III, a freely accessible critical care database,” *Scientific Data*, vol. 3, no. 1, p. 160035, 2016.

[15] C. E. Johnson, T. J. Pollard, L. Shen et al., “The Mimic code repository: enabling reproducibility in critical care research,” *Journal of the American Medical Informatics Association*, vol. 25, no. 1, pp. 32–39, 2017.

[16] C. Rhee, A. P. Scherag, H. D. Adhikari et al., “Prospective Studies Collaboration, G. Whitlock, S. Lewington et al., The obesity paradox in acute lung injury: the ‘weight’ is over,” *Chest*, vol. 131, no. 2, pp. 333–334, 2007.

[17] C. B. Hovind, K. O. Pedersen, L. B. Kristensen et al., “The obesity paradox in acute lung injury: the ‘weight’ is over,” *Chest*, vol. 131, no. 2, pp. 333–334, 2007.

[18] C. W. Hogue, J. D. Stearns, E. Colantuoni et al., “Obesity and mortality in critically ill patients: A retrospective cohort study of 108,927 patients,” *Critical Care Medicine*, vol. 36, no. 1, pp. 124–127, 2008.

[19] A. E. Johnson, J. D. Stone, L. A. Celi, and T. J. Pollard, “Obesity and mortality in critically ill patients: A prospective analysis of a large clinical database,” *Statistical science*, vol. 11, no. 3, pp. 189–228, 1996.

[20] T. J. DiCiccio and B. Efron, “Bootstrap confidence intervals,” *Statistical science*, vol. 11, no. 3, pp. 189–228, 1996.

[21] G. C. Foranow, P. Srikantan, M. R. Costanzo, G. B. Cintron, M. Lopatin, and ADHERE Scientific Advisory Committee and Investigators, “Adipose tissue as an endocrine organ,” *Obesity*, vol. 17, no. 1, p. 118, 2015.

[22] A. E. W. Johnson, T. J. Pollard, L. Shen et al., “MIMIC-III, a freely accessible critical care database,” *Scientific Data*, vol. 3, no. 1, p. 160035, 2016.

[23] C. Steiner, A. Elixhauser, and J. Schnaier, “The healthcare cost and utilization project: an overview,” *Effective Clinical Practice*, vol. 5, no. 3, pp. 143–151, 2002.

[24] C. W. Hogue, J. D. Stearns, E. Colantuoni et al., “Obesity and mortality in critically ill patients: A retrospective cohort study of 108,927 patients,” *Critical Care Medicine*, vol. 36, no. 1, pp. 124–127, 2008.

[25] C. W. Hogue, J. D. Stearns, E. Colantuoni et al., “Obesity and mortality in critically ill patients: A retrospective cohort study of 108,927 patients,” *Critical Care Medicine*, vol. 36, no. 1, pp. 124–127, 2008.

[26] C. H. Whitlock, S. Lewington et al., “Body-mass index and mortality in severe sepsis,” *Critical Care Medicine*, vol. 31, no. 4, pp. 810–818, 2015.

[27] C. Fleischmann, A. Scherag, N. K. N. Adhikari et al., “Prospective Studies Collaboration, G. Whitlock, S. Lewington et al., The obesity paradox in acute lung injury: the ‘weight’ is over,” *Chest*, vol. 131, no. 2, pp. 333–334, 2007.

[28] V. N. Ni, J. Luo, H. Yu et al., “Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis,” *Critical Care*, vol. 21, no. 1, p. 36, 2017.

[29] S. Wang, X. Liu, Q. Chen, C. Liu, C. Huang, and X. Fang, “The role of increased body mass index in outcomes of sepsis: a systematic review and meta-analysis,” *BMC Anesthesiology*, vol. 17, no. 1, p. 118, 2017.

[30] Y. Zhao, Z. Li, T. Yang, M. Wang, and X. Xi, “Is body mass index associated with outcomes of mechanically ventilated adult patients in intensive care units? A systematic review and meta-analysis,” *PloS One*, vol. 13, no. 6, article e0198669, 2018.

[31] T. G. Gaulton, C. M. MacNabb, M. E. Mikkelsen et al., “A retrospective cohort study examining the association between body mass index and mortality in severe sepsis,” *Internal and Emergency Medicine*, vol. 10, no. 4, pp. 471–479, 2015.

[32] C. W. Hogue, J. D. Stearns, E. Colantuoni et al., “The impact of obesity on outcomes after critical illness: a meta-analysis,” *Intensive Care Medicine*, vol. 35, no. 7, p. 1152, 2009.

[33] M. E. Akinnusi, L. A. Pineda, and A. A. El Solh, “Effect of obesity on intensive care morbidity and mortality: a meta-analysis,” *Critical Care Medicine*, vol. 36, no. 1, pp. 151–158, 2008.

[34] E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine organ,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 6, pp. 2548–2556, 2004.

[35] G. Winkler, S. Kiss, L. Kesztelyi et al., “Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level,” *European Journal of Endocrinology*, vol. 149, no. 2, pp. 129–135, 2003.

[36] T. W. Rice, “Obesity in acute lung injury: the ‘Weight’ is over,” *Chest*, vol. 131, no. 2, pp. 333–334, 2007.

[37] M. Hynynnen, V. P. Pettitj, O. Takkenen et al., “Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis,” *Shock*, vol. 20, no. 1, pp. 1–4, 2003.

[38] S. R. Bornstein, J. Licence, R. Tauchnitz et al., “Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm in cortisol and leptin secretion,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 83, no. 1, pp. 280–283, 1998.

[39] S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as an endocrine organ,” *Molecular and Cellular Endocrinology*, vol. 316, no. 2, pp. 129–139, 2010.

[40] S. Li, X. Hu, J. Xu et al., “Increased body mass index linked to greater short- and long-term survival in sepsis patients: a retrospective analysis of a large clinical database,” *International Journal of Infectious Diseases*, vol. 87, pp. 109–116, 2019.